Investigators receive grant to develop alternative to treat eye disease
May 24th 2021A team of researchers at the University of Cincinnati's Department of Chemistry and Department of Ophthalmology, in collaboration with researchers at Cincinnati Children's Hospital Medical Center and the Ohio State University, have received a four-year, $1.6 million grant from the National Institutes of Health/National Eye Institute to develop a drug delivery system that is more efficient and longer lasting than conventional eye injections.
Read More
Optogenetic methods restore partial vision in blind patient
May 24th 2021An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Read More
Alcon, Johnson & Johnson to face off in intellectual property dispute
May 17th 2021After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.
Read More
Results unveiled from phase 2/3 gene therapy study for XLRP
May 14th 2021While Biogen’s XIRIUS study did not meet its primary endpoint of demonstrating a statistically significant improvement in treated eyes, positive trends were observed across several clinically relevant prespecified secondary endpoints.
Read More
Minimally invasive retinal reattachment procedure leads to enhanced photoreceptor integrity
May 13th 2021A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.
Read More
Investigators develop technique to assess progression of sickle cell retinopathy
May 11th 2021Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss.
Read More
HHS to enforce prohibition of sex discrimination on basis of sexual orientation, gender identity
May 11th 2021In an announcement that could impact ophthalmologists, the Department of Health and Human Services’ Office for Civil Rights revealed this week that it will enforce a prohibition of discrimination on the basis of sexual orientation and gender identity.
Read More
Measuring visual fields with a cloud-based AI platform
May 7th 2021Mohamed Abou Shousha, MD, PhD, and Richard Parrish II, MD, discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.
Read More
Clinical results study dexamethasone implant effect on macular thickness
May 5th 2021Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Read More
Targeting neurodegenerative diseases with risuteganib
May 3rd 2021Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Read More
Artificial retina engineered from ancient protein now in space
April 14th 2021The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.
Read More